Shire’s NPS Buy Ahead Of FDA Natpara Vote Underscores Deal’s Logic
This article was originally published in The Pink Sheet Daily
Shire says it aims to use NPS’s rare-disease focus and pipeline to expand its expertise in gastrointestinal diseases - and voices confidence FDA will approve target’s Natpara drug to treat hypoparathyroidism.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.